EUVIMEDEUVIMED entdecken
Crossref

Profiling targets and potential target pairs of CAR-T cell therapy in clinical trials

Daiyan Zhang, Liyang Lyu, Shuo Han, Jiaqi Xu, Guang Hu, Qi Zhao, Yuanjia Hu

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2023.111273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Daiyan Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Universidade de Macau, Fundo para o Desenvolvimento das Ciências e da Tecnologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the approval of the first chimeric antigen receptor (CAR)-T product in 2017, the number of new CAR-T clinical trials worldwide exceeds 100 per year. 1649 clinical studies have been conducted to explore possible future clinical applications of targets or target pairs through different biotechnologies. In this study, we aim to take a data-driven analytical approach to explore potential dual-target pairs based on clinical trial information. We screened 1283 non-withdrawal interventional CAR-T clinical trials spanning 96 different targets and 74 target pairs from clinicaltrials.gov. Through the Circos plot and temporal network plots, the information between targets and indications was visualized. Based on the assumption that two targets of a target pair must target the same indication, five new target pairs were inferred, including CD19/CD7, CD19/CD5, CD19/CD37, and CD19/BAFFR and validated by expression pattern, literature and patent information. This study provides novel support for target profiling of CAR-T from the perspective of clinical trials and also provides a reference for researchers and developers to select new targets or target pairs of CAR-T cell therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenImmunotherapy, AdoptiveAntigens, CD19Cell- and Tissue-Based Therapy

Stichwörter der Autor:innen

CAR-TClinical trialsDual-targetTarget profiling

Substanzen

Receptors, Chimeric AntigenAntigens, CD19

Autor:innen und Institutionen

  • State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China.
  • Zhuhai Hengqin Haomai Technology Co., Ltd, Zhuhai, China.
  • School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China.
  • MoE Frontiers Science Center for Precision Oncology, Faculty of Health Sciences, University of Macau, Macao SAR, China.
  • State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China; Centre for Pharmaceutical Regulatory Sciences, University of Macau, Macao SAR,…

Förderung

  • Universidade de Macau
  • Fundo para o Desenvolvimento das Ciências e da Tecnologia

Zitieren

APA

Zhang, D., Lyu, L., Han, S., Xu, J., Hu, G., Zhao, Q., & Hu, Y. (2024). Profiling targets and potential target pairs of CAR-T cell therapy in clinical trials. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.111273

Vancouver

Zhang D, Lyu L, Han S, Xu J, Hu G, Zhao Q, et al. Profiling targets and potential target pairs of CAR-T cell therapy in clinical trials. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2023.111273

BibTeX
@article{Zhang2024,
  author = {Zhang, Daiyan and Lyu, Liyang and Han, Shuo and Xu, Jiaqi and Hu, Guang and Zhao, Qi and Hu, Yuanjia},
  title = {Profiling targets and potential target pairs of CAR-T cell therapy in clinical trials},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2023.111273}
}
Kostenlos starten →